ArticleProstate cancer and prostatic diseases2019
Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer.
Article in Prostate cancer and prostatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Radiomics vs radiologist in prostate cancer. Results from a systematic review.World journal of urology · 2023Pooled it
- Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review.European urology oncology · 2020Pooled it
- A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Trial
- A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.Prostate cancer and prostatic diseases · 2019Trial
- Implementation of a biparametric prostate MRI protocol with a recall system for intravenous contrast: an analysis of recall rates and comparison of PI-RADS category distribution.Abdominal radiology (New York) · 2026Article
- Article
- Fast prostate MRI vs. conventional multiparametric prostate MRI: comparison and outcomes.Abdominal radiology (New York) · 2025Article
- Comparisons of three scoring systems based on biparametric magnetic resonance imaging for prediction of clinically significant prostate cancer.Prostate international · 2024Article
- Utility of dynamic contrast enhancement for clinically significant prostate cancer detection.BJUI compass · 2024Article
- Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.Annals of internal medicine · 2024Article
- Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population.Abdominal radiology (New York) · 2024Article
- The potential role of the microbiota in prostate cancer pathogenesis and treatment.Nature reviews. Urology · 2023Review
- Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate-Unnecessary or Underutilised? A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer.Physical and engineering sciences in medicine · 2023Article
- Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis.Prostate cancer and prostatic diseases · 2023Article
- Could Biparametric MRI Replace Multiparametric MRI in the Management of Prostate Cancer?Life (Basel, Switzerland) · 2023Review
- Development and validation of a nomogram for predicting prostate cancer based on combining contrast-enhanced transrectal ultrasound and biparametric MRI imaging.Frontiers in oncology · 2023Article
- Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.World journal of urology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMultiparametric magnetic resonance imaging (MP-MRI) and MRI/ultrasound (US) fusion-guided biopsy are becoming more widely used techniques for prostate cancer (PCa) diagnosis and management. However, their widespread adoption and use, where available, are limited by cost and added time. These limitations could be minimized if a biparametric MRI (BP-MRI) focusing on T2-weighted and diffusion-weighted imaging is performed. Herein we report the cancer detection rate of BP-MRI compared with full MP-MRI.
methodsBiopsy-naive and prior negative biopsy patients with clinical suspicion for PCa underwent MP-MRI with an imaging protocol incorporating narrow field-of-view T2-weighted, diffusion-weighted, and DCE pelvic MRI. Then patients underwent MRI/US fusion-guided biopsy of target lesions between November 2013 and October 2017. The pathology results were compared to the positivity of the DCE sequence compared to the BP-MRI findings alone.
resultsThere were 648 targeted lesions biopsied in 344 patients. We defined biparametric screen filter positivity as both T2-weighted and diffusion-weighted imaging positivity for the same lesion. The majority of target lesions (552/648, 85%) were screen filter positive. For those that were screen filter negative, a minority (14/96, 15%) had DCE-positive findings. Of these, 2/3 (67%) cancer-positive cases were seen on T2-weighted imaging. For those 82 that were screen filter negative and DCE negative, the DCE phase would not have added imaging suspicion. Only 3/82 (3.7%) were cancer positive; 2 with low risk, grade group 1 cancer and 1 with intraductal carcinoma, all identified on targeted T2-weighted MRI positivity.
conclusionsBP-MRI for the evaluation of PCa and for guiding MRI/US fusion-targeted biopsy has the advantages of reducing cost, time, and contrast exposure of MP-MRI by eliminating the DCE phase. These benefits are realized without forfeiting valuable diagnostic information, as shown by similar cancer detection rates of BP-MRI and MP-MRI in this study, particularly for clinically significant cases of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.